ctDNA Guided Adjuvant Treatment With Elacestrant: TBCRC-068
Status:
RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial.
Phase:
PHASE2
Details
Lead Sponsor:
Yale University
Collaborators:
Johns Hopkins University Stemline Therapeutics, Inc.